Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia (CLL): Update Bulletin [November 2016]

Product Code:
596200627
Publication Date:
November 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Topics covered include expert opinions about the recent FDA label expansion of Novartis’ Arzerra (ofatumumab) to the relapsed setting in combination with fludarabine and cyclophosphamide (FC), and the negative EMA decision regarding the use of Arzerra as a maintenance therapy. Experts also discuss the amended design of the Phase III GENUINE study of TG Therapeutics’ ublituximab in combination with Janssen Biotech/AbbVie’s Imbruvica (ibrutinib) and offer further insights on the combination of TG Therapeutics’ TGR-1202 with ublituximab. Following AbbVie’s decision to return full development rights to Infinity Pharmaceuticals for duvelisib, KOLs also weigh in on what this could mean for the drug and its prospects in CLL. 

Highlights from this event update bulletin

  • How do KOLs view the expanded approval of Novartis’ Arzerra (ofatumumab) in combination with FC for the treatment of patients with relapsed CLL?
  • Will Arzerra and FC have a future role in the CLL treatment algorithm? If so, how will it compare to the other standards of care?
  • What does the negative EMA decision for Arzerra as maintenance mean for future maintenance therapy development in CLL?
  • What are KOL opinions on the amended design of the Phase III GENUINE study with TG Therapeutics’ ublituximab and Imbruvica?
  • How does the novel combination of TG Therapeutics’ ublituximab and TGR-1202 compare with other available therapies according to KOLs?
  • How does Infinity Pharmaceuticals’ duvelisib measure up against other treatments, and does it have a future in CLL?
  • What role will PI3 kinase inhibitors have in CLL moving forward?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved